Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
Blood Advances|May 8, 2020
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study resultsClaude Gardin, Cécile Pautas, Elise Fournier, et al.
Leukemia|April 21, 2023
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemiaNicolas Duployez, Loïc Vasseur, Rathana Kim, et al.
American Journal of Hematology|December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsSylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
Blood|August 19, 2021
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapyRaphael Itzykson, Elise Fournier, Céline Berthon, et al.
Leukemia|April 27, 2022
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemiaBryann Pardieu, Justine Pasanisi, Frank Ling, et al.
Blood|September 2, 2020
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemiaLaurène Fenwarth, Xavier Thomas, Stéphane de Botton, et al.
Rheumatology (Oxford, England)|September 10, 2015
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective studyArsène Mekinian, Eric Grignano, Thorsten Braun, et al.
NEJM Evidence|June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML TherapyMathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
Pageof 8